ClinicalTrials.gg
CompletedNCT02580591Updated Nov 2, 2018Results posted

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

A Phase 3 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 1, sponsored by Boehringer Ingelheim. Completed at 189 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-02.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
977
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.

Enrollment
Largest of 12
977 · median 49
Started
2015
with 1 other
Phase 3
4 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
4 of 12
Boehringer Ingelheim

Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written
  • Male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) > 1 year
  • C-peptide value of \< 0.7 ng/mL
  • Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total daily insulin >= 0.3 and \<= 1.5 U/kg
  • (HbA1c) >= 7.5% and \<= 10.0%
  • Good understanding of T1DM
  • Age >= 18 years
  • (BMI) >= 18.5 kg/m2
  • Estimated >= 30 mL/min/1.73 m2
  • Women of must use highly effective methods of
  • Compliance with trial medication administration between 80% and 120% during placebo run-in period Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
  • Pancreas, pancreatic islet cells or renal transplant recipient
  • T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and bolus insulin within last 3 months
  • Occurrence of severe hypoglycaemia within last 3 months and until randomisation
  • Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6
  • Irregular sleep/wake cycle
  • Acute coronary syndrome, stroke or (TIA) within last 3 months
  • Severe gastroparesis
  • Brittle diabetes
  • Liver disease
  • Eating disorders
  • Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen
  • Treatment with systemic
  • Change in dose of thyroid hormones within last 6 weeks and until randomisation
  • Cancer or treatment for cancer in the last five years
  • Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells
  • Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial
  • Alcohol or drug abuse
  • Intake of an drug in another trial within last 30 days Further exclusion criteria apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
977 participants (actual)

Study arms

  • Experimental
    Empagliflozin low dose

    Drug: Empagliflozin · Drug: Placebo

  • Experimental
    Empagliflozin high dose

    Drug: Empagliflozin · Drug: Placebo

  • Experimental
    Empagliflozin medium dose

    Drug: Empagliflozin · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])

    Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

  2. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))

    Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

Secondary outcomes

  1. Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)

    Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.

    Time frame: Week 5 to Week 26, Week 1 to Week 26

  2. Change From Baseline in Body Weight at Week 26

    Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

  3. Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26

    Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

  4. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26

    Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

07

Results

Posted Nov 2, 2018

Participant flow

A randomized, placebo-controlled, double-blind, parallel-group study compared 3 doses of empagliflozin (2.5 milligram (mg), 10 mg, and 25 mg) with placebo in patients with type 1 diabetes mellitus (T1DM) as adjunctive to optimized insulin therapy.

Participant flow — Overall Study
MilestonePlacebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Started242242248245
Treated241241248245
Completed224232235233
Not completed18101312
Withdrew: Adverse event0125
Withdrew: Protocol violation3211
Withdrew: Lost to follow-up5331
Withdrew: Withdrawal by subject6123
Withdrew: Not treated1100
Withdrew: Other than specified3252

Outcome measures

PrimaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])

Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Percentage (%)
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])
Percentage (%)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])0.20 ± 0.05-0.09 ± 0.05-0.25 ± 0.05-0.33 ± 0.05
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.28 · 99% CI -0.46 to -0.11Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.45 · 97.5% CI -0.60 to -0.30Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.52 · 97.5% CI -0.68 to -0.37Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
PrimaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))

Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Percentage (%)
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))
Percentage (%)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))0.21 ± 0.05-0.06 ± 0.05-0.23 ± 0.05-0.30 ± 0.05
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat Measurement · Mean difference (final values): -0.27 · 95% CI -0.40 to -0.14Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Median difference (final values): -0.44 · 97.5% CI -0.59 to -0.28Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.50 · 97.5% CI -0.66 to -0.35Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryRate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)

Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.

Time frame:
Week 5 to Week 26, Week 1 to Week 26
Reported as:
Least squares mean · Events per patient year
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
Events per patient yearPlacebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Week 5 to 266.13 (4.83 to 7.78)5.77 (4.53 to 7.34)7.37 (5.83 to 9.31)6.25 (4.94 to 7.91)
Week 1 to 266.62 (5.30 to 8.27)6.17 (4.93 to 7.73)8.33 (6.70 to 10.37)6.96 (5.58 to 8.67)
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Negative binomial model · Adjusted rate ratio (%): 0.940 · 95% CI 0.673 to 1.314Empagliflozin 2.5 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Negative binomial model · p = 0.2752 · Adjusted rate ratio (%): 1.202 · 97.75% CI 0.818 to 1.766Empagliflozin 10 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Negative binomial model · p = 0.9077 · Adjusted rate ratio (%): 1.020 · 97.75% CI 0.693 to 1.501Empagliflozin 25 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Negative binomial model · Adjusted rate ratio (%): 0.932 · 95% CI 0.682 to 1.274
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Negative binomial model · p = 0.1438 (This is a nominal p-value.) · Adjusted rate ratio (%): 1.258 · 95% CI 0.925 to 1.713Empagliflozin 10 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Negative binomial model · p = 0.7543 (This is a nominal p-value.) · Adjusted rate ratio (%): 1.051 · 95% CI 0.771 to 1.433Empagliflozin 25 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
SecondaryChange From Baseline in Body Weight at Week 26

Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Body Weight at Week 26
Kilogram (kg)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Body Weight at Week 260.21 ± 0.20-1.55 ± 0.20-2.83 ± 0.20-3.22 ± 0.20
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat Measurement · Mean difference (final values): -1.76 · 95% CI -2.32 to -1.20Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -3.04 · 99.75% CI -3.91 to -2.18Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -3.43 · 99.75% CI -4.30 to -2.57Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryChange From Baseline in Total Daily Insulin Dose (TDID) at Week 26

Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Unit/kilogram (U/kg)
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Unit/kilogram (U/kg)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26-0.011 ± 0.007-0.060 ± 0.007-0.080 ± 0.007-0.102 ± 0.007
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat Measurement · Mean difference (final values): -0.049 · 95% CI -0.069 to -0.030Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.070 · 99.75% CI -0.101 to -0.039Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -0.091 · 99.75% CI -0.122 to -0.060Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26

Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Millimeters of mercury (mmHg)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
SBP0.4 ± 0.7-1.7 ± 0.7-3.5 ± 0.7-3.4 ± 0.7
DBP0.0 ± 0.4-0.4 ± 0.4-1.8 ± 0.4-1.5 ± 0.4
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat MeasurementMix · Median difference (final values): -2.1 · 95% CI -3.9 to -0.2Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -3.9 · 99.75% CI -6.8 to -1.1Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = <0.0001 · Mean difference (final values): -3.7 · 99.75% CI -6.6 to -0.9Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 2.5 Milligram (mg) · Mixed effect Model Repeat Measurement · Mean difference (final values): -0.3 · 95% CI -1.5 to 0.9Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeat Measurement · p = 0.0047 · Mean difference (final values): -1.7 · 99.75% CI -3.6 to 0.1Mean Difference= Empagliflozin 2.5 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Mixed effect Model Repeat Measurement · p = 0.0202 · Mean difference (final values): -1.4 · 99.75% CI -3.3 to 0.4

Adverse events

Collected over From the first dose of trial medication until 7 days after last in-take of trial medication, up to 232 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Matching Empagliflozin0/241 (0%)16/241 (6.6%)153/241 (63.5%)
Empagliflozin 2.5 Milligram (mg)0/241 (0%)13/241 (5.4%)146/241 (60.6%)
Empagliflozin 10 mg0/248 (0%)21/248 (8.5%)172/248 (69.4%)
Empagliflozin 25 mg1/245 (0.4%)16/245 (6.5%)162/245 (66.1%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPlacebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
Diabetic ketoacidosisMetabolism and nutrition disorders2/2412/2416/2485/245
HypoglycaemiaMetabolism and nutrition disorders4/2413/2413/2480/245
KetosisMetabolism and nutrition disorders0/2411/2410/2483/245
KetoacidosisMetabolism and nutrition disorders1/2411/2413/2482/245
Angina unstableCardiac disorders0/2412/2410/2480/245
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2411/2410/2480/245
Abdominal painGastrointestinal disorders0/2410/2412/2480/245
VomitingGastrointestinal disorders0/2410/2412/2481/245
VertigoEar and labyrinth disorders1/2410/2410/2480/245
Eye haemorrhageEye disorders1/2410/2410/2480/245
Most frequent other events
Most frequent other events
EventPlacebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mg
HypoglycaemiaMetabolism and nutrition disorders144/241137/241162/248151/245
NasopharyngitisInfections and infestations24/24123/24122/24826/245
Urinary tract infectionInfections and infestations12/24112/2419/24816/245
Blood ketone body increasedInvestigations3/2414/24115/24810/245

Baseline characteristics

Randomised set (RS): All patients from the Screened set (SCR) who were randomised to trial medication, regardless of whether any trial medication was taken.

Age, Continuous
Age, Continuous(Years)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean42.3 ± 13.243.4 ± 14.342.3 ± 13.244.4 ± 13.643.1 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Female126120132121499
Male116122116124478
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Hispanic or Latino215220233224892
Not Hispanic or Latino2722152185
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Matching EmpagliflozinEmpagliflozin 2.5 Milligram (mg)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
American Indian or Alaska Native701513
Asian222511
Native Hawaiian or Other Pacific Islander10001
Black or African American5310422
White227234234231926
More than one race03104
Unknown or Not Reported00000
08

Study locations

189 sites
  • Healthscan Clinical Trials LLC
    Montgomery, Alabama 36106, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Valley Research
    Fresno, California 93720, United States
  • Marin Endocrine Care and Research
    Greenbrae, California 94904, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • William Sansum Diabetes Center
    Santa Barbara, California 93105, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • International Research Associates, LLC
    Hialeah, Florida 33012, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32225, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Physicians Research Associates, LLC
    Lawrenceville, Georgia 30046, United States
  • Sestron Clinical Research
    Marietta, Georgia 30060, United States
  • Eagle's Landing Diabetes and Endocrinology
    Stockbridge, Georgia 30281, United States
  • Northwest Endo Diabetes Research, LLC
    Arlington Heights, Illinois 60005, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • MODEL Clinical Research
    Baltimore, Maryland 21204, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Desert Endocrinology Clinical Research Center
    Henderson, Nevada 89052, United States
  • Palm Research Center
    Las Vegas, Nevada 89128, United States
  • Endocrine-Diabetes Care and Resource Center
    Rochester, New York 14607, United States
  • Endocrine Associates of Long Island, PC
    Smithtown, New York 11787, United States
  • Diabetes Endocrinology Research Center of Western New York
    Williamsville, New York 14221, United States
  • Diabetes and Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • Holzer Clinic LLC
    Gallipolis, Ohio 45631, United States
  • COR Clinical Research, LLC
    Oklahoma City, Oklahoma 73103, United States
  • Strand Physician Specialists dba Carolina Health Specialists
    Myrtle Beach, South Carolina 29572, United States
  • AM Diabetes and Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • University Diabetes and Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • Texas Diabetes & Endocrinology PA
    Austin, Texas 78749, United States
  • Texas Health Physicians Group
    Dallas, Texas 75218, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Endeavor Clinical Trials, PA
    San Antonio, Texas 78229, United States
  • Virginia Endocrinology Research
    Chesapeake, Virginia 23321, United States
  • Coffs Endocrine & Diabetes Services
    Coffs Harbour, New South Wales 2450, Australia
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
  • SA Endocrine Research P/L
    Keswick, South Australia 5035, Australia
  • Eastern Clinical Research Unit
    East Ringwood, Victoria 3135, Australia
  • Richmond Road and Diagnostic Treatment Centre
    Calgary, Alberta T2T 5C7, Canada
  • The Bailey Clinic
    Red Deer, Alberta T4N 6V7, Canada
  • Eastern Health (MUN)
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Centre for Studies in Family Medicine
    London, Ontario N6G 2M1, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Omnispec Recherche Clinique Inc.
    Mirabel, Quebec J7J 2K8, Canada
  • Applied Medical Informatics Research INC.
    Westmount, Quebec H3Z 1E5, Canada
  • Clinique des maladies Lipidiques de Quebec
    Quebec, G1V 4M6, Canada
  • University Hospital Brno
    Brno, 625 00, Czechia
  • Diahaza s.r.o.Intern.Med.Outpat.Clin.Dep.Diabetology,Holesov
    Holesov, 769 01, Czechia
  • AIDIN VK s.r.o.,Department Diabetology, Hranice
    Hranice, 753 01, Czechia
  • Univ. Hospital Kralovske Vinohrady
    Prague, 100 42, Czechia
  • DiaGolfova s.r.o., Department Diabetology, Prague
    Prague, 102 00, Czechia
  • Milan Kvapil s.r.o.,Diabetology ambulance,Prague
    Prague, 149 00, Czechia
  • ResTrial s.r.o.Diabetology Ambulance,Prague
    Prague, 18100, Czechia
  • HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki
    Helsinki, 00290, Finland
  • Mehiläinen Jyväskylä
    Jyväskylä, 40100, Finland
  • Satakunnan Diabetesasema, Pori
    Pori, 28100, Finland
  • FinnMedi Oy, Tampere
    Tampere, 33520, Finland
  • TYKS
    Turku, FI-20520, Finland
  • HOP Jean Minjoz
    Besancon, 25030, France
  • HOP Le Creusot
    Le Creusot, 71200, France
  • HOP Paris Saint-Joseph
    Paris, 75014, France
  • HOP Bichat
    Paris, 75018, France
  • HOP de Poitiers
    Poitiers, 86021, France
  • HOP Civil
    Strasbourg, 67091, France
  • HOP Rangueil
    Toulouse Cédex 04, 31059, France
  • Diabetes-Klinik Bad Mergentheim GmbH & Co. KG
    Bad Mergentheim, 97980, Germany
  • Diabetologische Schwerpunktpraxis, Bosenheim
    Bosenheim, 55545, Germany
  • Praxis Dr. Busch, Dortmund
    Dortmund, 44137, Germany
  • GWT-TUD GmbH
    Dresden, 01307, Germany
  • ZKS Südbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Praxis Dr. Kaiser, Frankfurt
    Frankfurt, 60388, Germany
  • Institut für Diabetesforschung Münster GmbH
    Münster, 48145, Germany
  • Diabetologische Schwerpunktpraxis
    Münster, 48153, Germany
  • Praxis Dr. Behnke, Neuwied
    Neuwied, 56564, Germany
  • Praxis Dr. Hilgenberg
    Rehburg-Loccum, 31547, Germany
  • "Korgialeneio-Benakeio" Hellenic Red Cross Hospital
    Athens, 115 26, Greece
  • General Hospital of Athens "Laiko"
    Athens, 11527, Greece
  • Univ. Gen. Hosp. of Ioannina
    Ioannina, 45500, Greece
  • General Hospital of Nikaia
    Nikaia, 18484, Greece
  • General Hopsital of Thessaloniki "Ippokrateio"
    Thessaloniki, 54642, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou"
    Thessaloniki, 57010, Greece
  • Clinexpert Kft.
    Budapest, 1033, Hungary
  • Synexus Magyarorszag Kft.
    Budapest, 1036, Hungary
  • University Debrecen Hospital
    Debrecen, 4032, Hungary
  • CRU Hungary Ltd, Private Practice, Miskolc
    Miskolc, 3529, Hungary
  • Clinfan SMO Ltd.
    Szekszard, 7100, Hungary
  • Csongrad Country Dr Bugyi Istvan Hosp.
    Szentes, 6600, Hungary
  • Zala Country Hospital, Diabetic Outpatient Clinic
    Zalaegerszeg, 8900, Hungary
  • Mater Misericordiae University Hospital
    Dublin, 7, Ireland
  • Inrca-Irccs
    Ancona, 60124, Italy
  • A.O. Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Osp. Campo di Marte
    Lucca, 55100, Italy
  • Azienda Ospedaliera Universitaria "Federico II"
    Napoli, 80131, Italy
  • Policlinico Gemelli
    Roma, 00168, Italy

Showing the first 100 of 189 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. PubMed 30287422 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2017, 20 months.

Results were first posted in Nov 2018, 1 year 1 month after primary completion. A results delay was requested in Jun 2018.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 20 months is above that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 20, 2015
StartActual
Dec 22, 2015
Primary completionActual
Sep 12, 2017
CompletionActual
Sep 20, 2017
Results delay requested
Jun 25, 2018
Results first posted
Nov 2, 2018
Last update
Nov 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02580591
Responsible party
Sponsor
First posted
Oct 20, 2015
Start date
Dec 22, 2015
Primary completion
Sep 12, 2017
Completion
Sep 20, 2017
Results posted
Nov 2, 2018
Last update
Nov 2, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion